![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » SICOR REACQUIRES MARKETING RIGHTS TO AAIPHARMA'S CALCITRIOL
SICOR REACQUIRES MARKETING RIGHTS TO AAIPHARMA'S CALCITRIOL
aaiPharma has announced that SICOR Pharmaceuticals, a wholly owned subsidiary of Teva Pharmaceutical Industries, has reacquired its U.S. marketing rights for calcitriol injection in exchange for certain payments to aaiPharma. Calcitriol injection vial is a drug used primarily to treat chronic kidney dialysis patients with abnormally low levels of calcium in their blood.
PharmaBiz.com (http://www.pharmabiz.com/article/detnews.asp?articleid=25424)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct